Abstract
Cancer patients develop cachexia due to systemic inflammation, negative protein and energy balance. Esperer Onco Nutrition (EON) has come up with innovative nutritional supplements (EON Therapy) that help patients take the rigours of cancer therapy thereby improving prognosis and Quality of Life (QoL). This Post-marketing surveillance study was undertaken on 38 volunteers to assess the impact of EON therapy on cachexia and QoL of patients undergoing curative treatment. Body weight and biochemical parameters of the volunteers were recorded at each visit. Volunteers were assessed using ECOG Scale and Malnutrition Screening Tool (MST) to assess impact of nutritional supplements on QoL. Weight loss was observed in most of the patients for first two visits but the patients gained weight over subsequent visits and average weight at end of the study was higher than initial weight. At the end of study 22 of 38 volunteers gained weight and 7 volunteers maintained initial weight. The biochemical parameters either showed improvement or remained same. The QoL analysis indicated a marked improvement in physical wellness and nutritional status and no adverse effects were reported. In conclusion, the study underlines importance of research based on nutritional supplements for cancer patients for better disease management and prognosis.
Highlights
Ever since the time of Hippocrates, cancer cachexia, with gross loss of skeletal muscle and adipose tissue, remains a clinical impasse often occurring in presence of malnutrition [1] [2]
Esperer Onco Nutrition (EON) has come up with innovative nutritional supplements (EON Therapy) that help patients take the rigours of cancer therapy thereby improving prognosis and Quality of Life (QoL)
It is evident that pro-inflammatory cytokine activity gets elevated during progression of the disease marked by the generation of acute-phase response (APR) proteins, viz, C-reactive protein (CRP) and fibrinogen
Summary
Ever since the time of Hippocrates, cancer cachexia, with gross loss of skeletal muscle and adipose tissue, remains a clinical impasse often occurring in presence of malnutrition [1] [2]. Malnutrition is a persistent complication in cancer patients, whose ubiquity and degree largely pivot on tumour stage and site of occurrence [3]. Bleak ramifications of the malady are extended hospitalization, impaired response to cancer treatment, a higher degree of systemic treatmentrelated toxicity, compromised competency of immune system, reduced level of activity, vitiated Quality of Life (QoL) with an unpleasant prognosis rendering unremitting emotional, social and financial burden on the families of afflicted people [4] [5]. Of a myriad of contributing factors, altered metabolic activity in patients with advanced cancer, often indicated by a systemic inflammatory response syndrome, is known to propel catabolism which redisseminates body resources leading to enhanced morbidity and mortality [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
